Literature DB >> 5789562

Experimentally induced mononucleosis-like heterophile antibodies in man.

J Leikola, K Aho.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1969        PMID： 5789562      PMCID： PMC1579082     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


× No keyword cloud information.
  15 in total

1.  [New methods for a serological diagnosis of infectious mononucleosis].

Authors:  J TOMCSIK
Journal:  Bull Schweiz Akad Med Wiss       Date:  1960-10

2.  Specific heterophile antibody from infectious mononucleosis serum.

Authors:  K Yoshida; A Nahmias
Journal:  Proc Soc Exp Biol Med       Date:  1967-02

3.  Quantitative aspects of mononucleosis antibodies.

Authors:  J Leikola
Journal:  Int Arch Allergy Appl Immunol       Date:  1968

4.  Infectious mononucleosis: complement-fixing antibodies to herpes-like virus associated with Burkitt lymphoma.

Authors:  P Gerber; D Hamre; R A Moy; E N Rosenblum
Journal:  Science       Date:  1968-07-12       Impact factor: 47.728

5.  Infectious mononucleosis. Clinical manifestations in relation to EB virus antibodies.

Authors:  J C Niederman; R W McCollum; G Henle; W Henle
Journal:  JAMA       Date:  1968-01-15       Impact factor: 56.272

6.  Studies of the nature of incomplete anti-Rh antibodies.

Authors:  J Leikola
Journal:  Int Arch Allergy Appl Immunol       Date:  1967

7.  Antibody formation in infectious mononucleosis. II. Other 19S antibodies and false-positive serology.

Authors:  R L Carter
Journal:  Br J Haematol       Date:  1966-05       Impact factor: 6.998

8.  Relation of Burkitt's tumor-associated herpes-ytpe virus to infectious mononucleosis.

Authors:  G Henle; W Henle; V Diehl
Journal:  Proc Natl Acad Sci U S A       Date:  1968-01       Impact factor: 11.205

9.  Studies on infectious mononucleosis. I. Antibodies.

Authors:  J E Kostinas; E F Cantow
Journal:  Am J Med Sci       Date:  1966-12       Impact factor: 2.378

10.  Relation between Epstein-- Barr viral and cell membrane immunofluorescence in Burkitt tumor cells. II. Comparison of cells and sera from patients with Burkitt's lymphoma and infectious mononucleosis.

Authors:  G Klein; G Pearson; G Henle; W Henle; V Diehl; J C Niederman
Journal:  J Exp Med       Date:  1968-11-01       Impact factor: 14.307
View more
  5 in total

1.  Infectious mononucleosis: self-limited lymphoproliferation.

Authors:  D P Stites
Journal:  West J Med       Date:  1977-06

2.  Failure to detect heterophile antigens in Epstein-Barr virus-infected cells and to demonstrate interaction of heterophile antibodies with Epstein-Barr virus.

Authors:  W Henle; G Henle; J Hewetson; G Rocchi; J Leikola
Journal:  Clin Exp Immunol       Date:  1974-06       Impact factor: 4.330

3.  A serum inhibitor of the heterophile antibody in infectious mononucleosis.

Authors:  K Aho; J Leikola
Journal:  Clin Exp Immunol       Date:  1974-01       Impact factor: 4.330

4.  Epstein-Barr virus. Heterophile responses in squirrel monkeys inoculated with virus-transformed autologous leukocytes.

Authors:  T Shope; G Miller
Journal:  J Exp Med       Date:  1973-01-01       Impact factor: 14.307

5.  Immunizations with diverse sarbecovirus receptor-binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability.

Authors:  Deborah L Burnett; Katherine J L Jackson; David B Langley; Anupria Aggrawal; Alberto Ospina Stella; Matt D Johansen; Harikrishnan Balachandran; Helen Lenthall; Romain Rouet; Gregory Walker; Bernadette M Saunders; Mandeep Singh; Hui Li; Jake Y Henry; Jennifer Jackson; Alastair G Stewart; Franka Witthauer; Matthew A Spence; Nicole G Hansbro; Colin Jackson; Peter Schofield; Claire Milthorpe; Marianne Martinello; Sebastian R Schulz; Edith Roth; Anthony Kelleher; Sean Emery; Warwick J Britton; William D Rawlinson; Rudolfo Karl; Simon Schäfer; Thomas H Winkler; Robert Brink; Rowena A Bull; Philip M Hansbro; Hans-Martin Jäck; Stuart Turville; Daniel Christ; Christopher C Goodnow
Journal:  Immunity       Date:  2021-10-29       Impact factor: 43.474
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.